Full Text
Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC)- A Network Meta-Analysis vs. New Therapeutic Options

Abstract

Authors

S Popat A Mellemgaard M Reck C Hastedt

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×